Clot time ratio (CTR) and relation to treatment outcome in patients with atrial fibrillation treated with Rivaroxaban.
Journal Information
Full Title: Thromb J
Abbreviation: Thromb J
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Peripheral Vascular Disease
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Ethics approval and consent to participateThe Medical Ethical Committee of the Slovenian Ministry of Health. Consent for publicationNot applicable. Competing interestsLO is a full-time employee at Nordic Biomarker who developed the test MRX PT DOAC. ET is a consultant to Nordic Biomarker. Competing interests LO is a full-time employee at Nordic Biomarker who developed the test MRX PT DOAC. ET is a consultant to Nordic Biomarker."
"Funding Nordic Biomarker funded the study, application for extension of ethical approval, collection of samples from biobank, transport of samples to new laboratory. Salary for LO, and consultant fee for ET. This work was supported by the Slovenian Research and Innovation Agency."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025